Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

January 8, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805534/0/en/Biomea-Fusion-Announces-Dosing-of-First-Type-1-Diabetes-Patient-in-Phase-II-Study-COVALENT-112-with-BMF-219.html

REDWOOD CITY, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced dosing of the first patient with type 1 diabetes in the U.S. in its ongoing Phase II study (COVALENT-112) evaluating BMF-219, a novel, investigational covalent menin inhibitor, as a potential treatment for patients with type 1 diabetes.

Read more at globenewswire.com

Related news for (BMEA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.